

Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India

- Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M.

- Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, support weight-loss, and reduce cardiovascular- renal risks in patients with type 2 diabetes mellitus (T2DM).^{1,2,3} Empagliflozin has also demonstrated benefits in heart failure (HF) patients by lowering the cardiovascular (CV) death or hospitalization for HF.^{4,5}

Mumbai, India, March 12, 2025: Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk.¹

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety⁶. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.¹

In addition to cardiovascular benefits, studies have highlighted the effectiveness of Empagliflozin and its combinations. A 24-week study found that a twice daily combination of Empagliflozin (12.5 mg) and Metformin (500/1000 mg) helped people with T2DM lower their blood sugar levels (HbA1c by 1.9% to 2.1%), lose weight (3 to 3.8 kg), and reduce fasting blood sugar (by 43.2 to 50.4 mg/dL), with all results being highly significant.² Another 24-week study showed that Empagliflozin (10/25 mg) with Linagliptin (5 mg) helped patients lower their HbA1c (by 1.24%), lose weight (by 2 to 2.7 kg), and reduce fasting blood sugar (by 28.21 to 29.55 mg/dL), proving more effective than either medicine alone.³

Commenting on the launch, Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd., said, "Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively."

Glenmark's Glempa range is designed to cater to diverse patient needs by offering three treatment options that enhance treatment flexibility and effectiveness. Glempa (Empagliflozin 10mg/25mg) serves as a standalone SGLT2 inhibitor to improve glycaemic control while reducing cardiovascular risks. Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) is a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio renal risks.^{1,7} Meanwhile, Glempa M (Empagliflozin 12.5 mg + Metformin 500/1000 mg) combines the benefits of SGLT2 inhibition with the proven efficacy of Metformin, making it an optimal choice for patients needing stronger glycaemic control.

With Cardiovascular diseases and diabetes cases on the rise, Glenmark's Glempa range aims to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India.

----End---

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardio-metabolic, respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram ([glenmark_pharma](https://www.instagram.com/glenmark_pharma)).

Glenmark's expertise in Cardiometabolic care

Glenmark has a strong legacy of bringing in new, effective, and affordable treatment options for Cardiometabolic care. In 2004, Glenmark was the 1st to introduce Telmisartan with the brand Telma in India and now offers a complete basket of Telma range in Cardiology, making it the biggest brand franchise of Indian Pharmaceutical market. . In 2005, Glenmark was first to introduce Eplerenone with brand EPTUS in Heart failure management. In 2015, Glenmark launched the DPP4 inhibitor, Teneligliptin (Zita Plus[®] and Ziten[®]), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus[®] and Ziten-M[®]) which disrupted the entire DPP4 market in India. Glenmark later introduced Remogliflozin (Remo[®] and Remozen[™]), a novel SGLT-2 inhibitor in 2019; and subsequently, its combinations (Remo-V[®], Remozen[™]- V, Remo MV[®], and Remozen[™] MV). In 2023, Glenmark introduced Sacu V (Sacubitril Valsartan) thus expanding the Heart Failure management portfolio. In 2024, Glenmark was the first to launch biosimilar for Liraglutide (Lirafit[®]), a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in India, marking its entry into the injectable anti-diabetic market. The launch of Glempa, Glempa-L, and Glempa-M further strengthens Glenmark's commitment to enhancing Cardiometabolic care.

Prevalence of diabetes in India

As per the ICMR-INDIAB study conducted between October 2008 and December 2020, the overall weighted prevalence of diabetes was 11.4%⁸. In India, the annual incidence of heart failure attributed to conditions such as coronary heart disease, hypertension, obesity, diabetes, and rheumatic heart disease was conservatively estimated to be 491,600 to 1.8 million cases⁹. According to IQVIA™ sales data for the 12-month period ending January 2023 (MAT January 2025), the market for Empagliflozin and combinations is 642 Crores, and that of all SGLT2 inhibitors and combinations is 2904 Crores.

For more information, please contact

Udaykumar Murthy | corpcomm@glenmarkpharma.com | +91 9960377617

References:

- ¹ Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England journal of medicine*. 2015 Nov 26; 373(22):2117-28.
- ² Hadjadj S, et al. Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes. *Diabetes Care*. 2016; 39(10):1718-28.c
- ³ Lewin A, et al. Initial Combination of Empagliflozin and Linagliptin in Type 2 Diabetes. *Diabetes Care*. 2015; 38(3):394-402.
- ⁴ Packer M Et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *New England Journal of Medicine*. 2020 Oct 8;383(15):1413-24
- ⁵ Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. *New England Journal of Medicine*. 2021 Oct 14;385(16):1451-61.:
- ⁶ Prescribing information of Empagliflozin
- ⁷ Rosenstock J et al; CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA*. 2019 Jan 1;321(1):69-79.
- ⁸ Anjana RM et al; ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet Diabetes Endocrinol*. 2023 Jul;11(7):474-489.
- ⁹ Feng, J, Zhang, Y, Zhang, J. Epidemiology and Burden of Heart Failure in Asia. *JACC: Asia*. 2024 Apr, 4 (4) 249–264.